Introduction and Welcome (ID 5985)
Moving the Needle in HER2 Positive Gastroesophageal Cancer (ID 5986)
Changing GEC Patient Care with IO plus Chemotherapy in First-Line (ID 5987)
The IO Revolution of Patient Treatment in HCC (ID 5988)
Changing the Treatment Paradigm in First-Line Biliary Tract Cancers (ID 5989)
Treating GI Patients in Europe Based on Tumor Characteristics (ID 5990)
Final Q&A and Discussion Session (ID 5991)
Summary and Adjournment (ID 5992)
